Simon J. Hume

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B.

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B.

Journal: The Journal of infectious diseases

Published: September 11, 2025

Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.

Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.

Journal: The Journal of infectious diseases

Published: September 11, 2025

Accelerated impact of alcohol-associated hepatitis on healthcare utilisation during the COVID-19 pandemic.

Accelerated impact of alcohol-associated hepatitis on healthcare utilisation during the COVID-19 pandemic.

Journal: Internal medicine journal

Published: August 31, 2025

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.

Journal: Alimentary pharmacology & therapeutics

Published: June 21, 2025

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B.

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B.

Journal: Alimentary pharmacology & therapeutics

Published: November 28, 2024

Reply to Yu and Chen.

Reply to Yu and Chen.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: October 04, 2024

Individualizing the Approach to Stopping Nucleos(t)ide Analogs: Can We Use a Low HBsAg Threshold to Predict a High Chance of Functional Cure and Minimal Risk of Hepatic Decompensation?

Individualizing the Approach to Stopping Nucleos(t)ide Analogs: Can We Use a Low HBsAg Threshold to Predict a High Chance of Functional Cure and Minimal Risk of Hepatic Decompensation?

Journal: The American journal of gastroenterology

Published: April 15, 2024

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 06, 2024

Editorial on "Maximize Donor Cornea Use in a Hepatitis B Endemic Area via Serology Matching".

Editorial on "Maximize Donor Cornea Use in a Hepatitis B Endemic Area via Serology Matching".

Journal: Transplantation

Published: January 27, 2023

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Journal: Hepatology communications

Published: December 06, 2022

A Case Series of Patients With Acute Liver Allograft Rejection After Anti-SARS-CoV-2 mRNA Vaccination.

A Case Series of Patients With Acute Liver Allograft Rejection After Anti-SARS-CoV-2 mRNA Vaccination.

Journal: Transplantation

Published: April 15, 2022

COVID-19 and its impact on endoscopy services: what is the threshold for missed malignant diagnosis?

COVID-19 and its impact on endoscopy services: what is the threshold for missed malignant diagnosis?

Journal: Gut

Published: August 10, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026